相关实验视频
Updated: Jul 15, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
向肝脏的塞鲁洛普拉斯通过调节胆酸代谢来缓解非酒精性脂肪肝炎
Quanxin Jiang1, Ning Wang1, Sijia Lu1
1Shanghai Diabetes Institute, Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China.
向塞鲁洛普拉斯 (Cp) 显示出对治疗非酒精性脂肪肝炎 (NASH) 的希望. 降低肝细胞中的Cp水平可以缓解NASH症状,并恢复胆酸代谢,提供新的治疗途径.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 代谢疾病 代谢疾病
- 生物化学 生物化学
背景情况:
- 非酒精性脂肪肝炎 (NASH) 是一种进展性肝病,目前没有药理治疗方法.
- NASH的特点是脂肪积累,炎症和纤维化,可能导致肝硬化和肝癌.
研究的目的:
- 为了研究向青素 (Cp) 在NASH治疗中的治疗潜力.
- 了解肝脏Cp在NASH病变发生中的作用.
主要方法:
- 在NASH患者和小鼠模型中分析肝脏Cp水平.
- 在饮食诱导的NASH小鼠模型中,肝细胞特异性Cp剥离.
- 转录学和代谢学,以分析胆酸代谢中的变化.
主要成果:
- 肝脏Cp在NASH中显著上调.
- 细胞核切除减轻了饮食诱导的纳氏瘤,减少了脂质积累,炎症和纤维化.
- 通过调节Cyp7a1和Cyp8b1的胆酸代谢,Cp删除恢复了胆酸代谢,增强了胆酸合成.
结论:
- 球状质在NASH的发展中起着至关重要的作用.
- 针对肝脏Cp是NASH治疗的一个有前途的治疗策略.
- 细胞调节会影响胆汁酸代谢,为NASH的病变产生提供了洞察力.
更多相关视频
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
相关概念视频
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Hepatic Drug Excretion: Influencing Factors
Lipid-Lowering Drugs: Statins and Miscellaneous Agents